IN2015DN00202A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00202A
IN2015DN00202A IN202DEN2015A IN2015DN00202A IN 2015DN00202 A IN2015DN00202 A IN 2015DN00202A IN 202DEN2015 A IN202DEN2015 A IN 202DEN2015A IN 2015DN00202 A IN2015DN00202 A IN 2015DN00202A
Authority
IN
India
Prior art keywords
mula
inhibitors
compounds
formula
neutrophil elastase
Prior art date
Application number
Inventor
Carmelida Capaldi
Robert Andrew Heald
Nicholas Charles Ray
Jonathan Mark Sutton
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of IN2015DN00202A publication Critical patent/IN2015DN00202A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds of formula (I) are inhibitors of neutrophil elastase wherein Ri, R2, Ai, A2, A , assume meanings as defined in for mula (I).
IN202DEN2015 2012-07-12 2013-07-10 IN2015DN00202A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12176079 2012-07-12
EP13158756 2013-03-12
PCT/EP2013/064603 WO2014009425A1 (en) 2012-07-12 2013-07-10 Inhibition of enzymes

Publications (1)

Publication Number Publication Date
IN2015DN00202A true IN2015DN00202A (en) 2015-06-12

Family

ID=48953361

Family Applications (1)

Application Number Title Priority Date Filing Date
IN202DEN2015 IN2015DN00202A (en) 2012-07-12 2013-07-10

Country Status (10)

Country Link
US (1) US9199984B2 (en)
EP (1) EP2872509B1 (en)
KR (1) KR20150031318A (en)
CN (1) CN104428300B (en)
AR (1) AR091737A1 (en)
BR (1) BR112015000507A2 (en)
CA (1) CA2878792A1 (en)
IN (1) IN2015DN00202A (en)
RU (1) RU2638537C2 (en)
WO (1) WO2014009425A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2933725A1 (en) 2013-12-16 2015-06-25 Chiesi Farmaceutici S.P.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors
US9487528B2 (en) 2014-06-09 2016-11-08 Chiesi Farmaceutici S.P.A. Compounds
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9409870B2 (en) 2014-12-15 2016-08-09 Chiesi Farmaceutici S.P.A. Compounds
AR108608A1 (en) 2016-05-31 2018-09-05 Chiesi Farm Spa AHR INHIBITING PIRAZOLIL CARBONIL DERIVATIVES
BR112018074608B1 (en) 2016-05-31 2024-01-23 Chiesi Farmaceutici S.P.A COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND
WO2017207433A1 (en) * 2016-05-31 2017-12-07 Chiesi Farmaceutici S.P.A. Hetetocyclic compounds for use in the treatment of a disease in which hne is implicated
EP3586216A4 (en) 2017-02-27 2020-12-30 Bálint, Géza INTELLIGENT DEVICE WITH A DISPLAY THAT ALLOWS SIMULTANEOUS MULTIFUNCTIONAL HANDLING OF THE DISPLAYED INFORMATION AND / OR DATA
EP4003973B1 (en) 2019-07-23 2024-11-20 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
AU2020317609A1 (en) 2019-07-23 2022-02-24 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
EP4031138A1 (en) 2019-09-17 2022-07-27 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
WO2021069567A1 (en) 2019-10-09 2021-04-15 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
FI4041721T3 (en) 2019-10-09 2024-06-03 Bayer Ag Novel heteroaryl-triazole compounds as pesticides
KR20220097434A (en) * 2019-11-01 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 Substituted Pyrazole Compounds as Toll Receptor Inhibitors
TW202134226A (en) 2019-11-18 2021-09-16 德商拜耳廠股份有限公司 Novel heteroaryl-triazole compounds as pesticides
EP4106757B1 (en) 2020-04-16 2023-08-23 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
JP2023542789A (en) * 2020-09-28 2023-10-12 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド Pyrazole compounds and their preparation and use
CN113480486B (en) * 2021-07-30 2022-05-24 赣南师范大学 3-amido-1, 2,4-triazole derivative and preparation method and application thereof
EP4419102A1 (en) 2021-10-20 2024-08-28 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259504A (en) 1979-08-27 1981-03-31 American Cyanamid Company Substituted 1H-1,2,4-triazoles
US4451471A (en) 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
US4576958A (en) 1984-01-23 1986-03-18 E. I. Du Pont De Nemours And Company Antihypertensive 4,5-diaryl-1H-imidazole-2-methanol derivatives
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
ES2184633B1 (en) 2001-08-07 2004-08-01 J. URIACH & CIA, S.A. PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 4- (IMIDAZOL-1-IL) BENCENOSULFONAMIDE.
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
MX2007004179A (en) 2004-10-07 2007-06-07 Warner Lambert Co Triazolopyridine derivatives as antibacterial agents.
US7902374B2 (en) 2005-05-06 2011-03-08 Universal Display Corporation Stability OLED materials and devices
US20080125587A1 (en) 2006-05-25 2008-05-29 Chimmanamada Dinesh U Synthesis of triazole compounds that modulate HSP90 activity
EA017297B1 (en) * 2007-11-06 2012-11-30 Астразенека Аб Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
PE20091953A1 (en) 2008-05-08 2010-01-09 Du Pont SUBSTITUTED AZOLS AS FUNGICIDES
CN102131805A (en) * 2008-06-20 2011-07-20 百时美施贵宝公司 Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
EP2307411B1 (en) * 2008-06-20 2014-01-01 Bristol-Myers Squibb Company Triazolopyridine compounds useful as kinase inhibitors
DE102009004197A1 (en) * 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclic fused diaryldihydropyrimidine derivatives and their use
BR112012007322A2 (en) * 2009-10-02 2017-06-06 Astrazeneca Ab 2-pyridone compound used as neutrophil elastase inhibitors

Also Published As

Publication number Publication date
EP2872509B1 (en) 2016-09-14
CA2878792A1 (en) 2014-01-16
US20140018345A1 (en) 2014-01-16
CN104428300A (en) 2015-03-18
EP2872509A1 (en) 2015-05-20
HK1207078A1 (en) 2016-01-22
RU2638537C2 (en) 2017-12-14
RU2015104644A (en) 2016-08-27
WO2014009425A1 (en) 2014-01-16
AR091737A1 (en) 2015-02-25
US9199984B2 (en) 2015-12-01
BR112015000507A2 (en) 2017-06-27
CN104428300B (en) 2016-11-09
KR20150031318A (en) 2015-03-23

Similar Documents

Publication Publication Date Title
IN2015DN00202A (en)
UY34092A (en) NEW COMPOUNDS AS JAK INHIBITORS
AU2013291345B2 (en) Composition for controlling plant disease and application therefor
UY34051A (en) PIRROLOTRIAZINONA DERIVATIVES AS PI3K INHIBITORS
CR20140024A (en) METALOENZYM INHIBITING COMPOUNDS
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
UY34156A (en) METALOENZYM INHIBITING COMPOUNDS
PH12014502169A1 (en) N-cyclylamides as nematicides
UY34145A (en) METALOENZYM INHIBITING COMPOUNDS
UY34654A (en) BETA-SECRETASA INHIBITORS
UY33958A (en) GLUCOSILCERAMIDE SINTASA INHIBITORS
PH12012501650B1 (en) Heterocyclic compound
MX341456B (en) Amino-quinolines as kinase inhibitors.
IL228239A0 (en) Derivatives of 4,3-dihydro-pyrrolo[2.1-[a pyrazine-1-ylamine are effective as beta-saccharatase (bace) inhibitors
UY34300A (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF KINASE c-Kit
UY33930A (en) NEW QUINASE INHIBITORS
UY33929A (en) TETRAS REPLACED CYCLHEXYL COMPOUNDS AS QUINASE INHIBITORS
UY34523A (en) BETULINA DERIVATIVES
IN2015DN00598A (en)
IN2015DN01061A (en)
UA111744C2 (en) REPLACED PYRIDOPORASINS AS SYK INHIBITORS
CR20130539A (en) TRIAZOLOPIRIDINS
MX336865B (en) Imidazopyridazines as akt kinase inhibitors.
IN2014MN01637A (en)
JO3063B1 (en) Innovative compound and methods for its production